Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 1993Journal of Hypertension

Role of L-arginine-nitric oxide pathway in hypertension

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does intravenous L-arginine alter haemodynamic parameters and neuroendocrine hormones in patients with hypertension?

Population

16 patients with hypertension

Design

Case_series

Follow-up

During administration

Authors

KHKeiichi HishikawaTNToshio NakakiHSHiromichi Suzuki

Discussion

Loading...

Member takes

Overview

Hypothesis-generating in a single case; leaves open any therapeutic role for L-arginine in hypertension.

Key Points

  • To evaluate the impact of intravenous L-arginine administration on hemodynamics, neuroendocrine hormone levels, and markers of nitric oxide release in patients with essential and secondary hypertension.
  • Enrolled 16 hypertensive patients, including 10 with essential hypertension and 6 with secondary hypertension (3 renovascular hypertension and 3 primary aldosteronism).
  • Administered intravenous L-arginine while tracking mean arterial pressure, heart rate, cardiac output, and total peripheral resistance.
  • Measured in vivo markers of nitric oxide synthesis (plasma cyclic GMP, plasma citrulline, urinary nitrite/nitrate) alongside neuroendocrine parameters (catecholamines, plasma renin activity, plasma aldosterone).
  • L-Arginine administration decreased mean arterial pressure and total peripheral resistance while increasing heart rate, cardiac output, and indicators of nitric oxide release.
  • Plasma aldosterone levels decreased significantly across all patients, while catecholamines and plasma renin activity showed no significant compensatory increases, except for renin in renovascular hypertension.

Structured PICO

Does intravenous L-arginine alter haemodynamic parameters and neuroendocrine hormones in patients with hypertension?

P
Population
16 patients with hypertension (10 with essential hypertension and 6 with secondary hypertension [3 renovascular, 3 primary aldosteronism])
I
Intervention
Intravenous L-arginine
O
Outcome
Changes in haemodynamic parameters (blood pressure, heart rate, cardiac output, total peripheral resistance), neuroendocrine hormones (catecholamines, plasma renin activity, plasma aldosterone), and indicators of NO releasesurrogate

Intravenous L-arginine produces a vasodilatory effect via increased NO production and modulates neuroendocrine hormone release, including decreasing aldosterone, in hypertensive patients.

Cite This Study

Hishikawa et al. (1993) studied this question.

synapsesocial.com/papers/6a10eea55e6663f9d264b03bhttps://doi.org/10.1097/00004872-199306000-00008
View Full Paper
Ask AI
Bookmark
Share